Colleagues I’ve been wading through the UK #governments second 5-year anti-AMR action plan, “Confronting #AntimicrobialResistance 2024-20...

Botanical compounds, that we call cPACs exist in nature and having been patented by UroPharma for #urinarytract use, are being investigated by the company. They are for incorporation into a #lubricant urethral gel for safer urinary catheterisation, because the first line of defence against CAUTI is to prevent the bacteria getting into the bladder in the first place! #Urinary #catheters are such essential clinical tools that over a billion units are used annually with numbers

UroPharma produced #intravesical drug-delivery technology to bring, under licence, better cystitis (lower #UTI) treatments. For decades,...

For some reason, we long assumed that #bacteria in the extra-systemic, #urinary cavity are subject to the same conditions as in other tissue infections, but they aren’t. #Antibiotics get to other tissue infections via blood whereas #cystitis #pathogens encounter antibiotics in #urine. That’s a big difference, first of all, blood pH range is narrow, so an antibiotic’s MIC (minimum inhibitory concentration) is predictable there. The urinary pH range is very wide. Antibiotic MIC

#Epithelia line tissue surfaces that the outside world can directly access, such as skin, sclera, mouth, gut, vagina, #bladder and...

Homeostatic mechanisms optimise our cellular chemistry. #antibiotics treatments are developed specifically to work in our narrow-band homeostatic chemical milieu to be delivered through blood to #infection sites for intimate combat with #bacterial invaders. With #cystitis, the bacteria are planktonic in urine and attached to urothelial cell membranes, so are too far away to be influenced by that approach. For #antibiotic tablets to have any chance to be effective against cy